[Federal Register Volume 86, Number 71 (Thursday, April 15, 2021)]
[Notices]
[Page 19902]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07718]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on March 31, 2021, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development & 
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery 
Consortium, Inc.'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Novartis Pharma AG, Basel, SWITZERLAND, has been added as 
a party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to Section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to Section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on January 8, 
2021. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on January 28, 2021 (86 FR 7415).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2021-07718 Filed 4-14-21; 8:45 am]
BILLING CODE P